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ABSTRACT 
  
Context: The perioperative management of patients under dual antiplatelet therapy after 
myocardial infarction, cerebrovascular event or coronary stent implantation represents an 
increasingly frequent issue for urologists and anaesthesiologists.  
Objective: To assess the current scientific evidence and propose strategies concerning the 
management of urologic patients under antiplatelet therapy. A Medline & PubMed search was 
conducted for articles related to antiplatelet therapy after myocardial infarction, coronary stents 
and cerebrovascular events, and to the management of aspirin and/or clopidogrel in the context of 
surgery.  
Results: Early discontinuation of antiplatelet therapy in secondary prevention is associated with a 
high risk of coronary thrombosis, further increased by the hypercoagulable state induced by 
surgery. Aspirin has recently been recommended to be a lifelong therapy. Clopidogrel is 
mandatory for 6 weeks after myocardial infarction and bare-metal stents, and for 12 months after 
drug-eluting stents. Surgery must be postponed beyond these waiting periods, or be performed 
under dual antiplatelet therapy, because withdrawal therapy increases 5-10 times the risk of 
postoperative myocardial infarction, stent thrombosis or death. The shorter the waiting periods 
between revascularisation and surgery, the higher is the risk of adverse cardiac events. The risk of 
surgical haemorrhage is increased approximately 20% by aspirin and 50% by clopidogrel. 
Conclusions: The present review of the literature demonstrates that the risk of coronary 
thrombosis when antiplatelet agents are withdrawn before surgery is generally higher than the 
risk of surgical haemorrhage when antiplatelet agents are upheld. However, this issue has not yet 
been sufficiently evaluated in urologic patients and in many instances during urologic surgery the 
risk of bleeding might be exceedingly dangerous. In this problematic situation, a thorough 
dialogue between surgeon, cardiologist and anaesthesiologist is essential to determine all risk 
factors and to define the best possible strategy for each individual patient. 
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INTRODUCTION 
 
More than 2 million patients undergo percutaneous coronary intervention (PCI) with stents each 
year. Since 5% of them present for surgery within the following 12 months, the perioperative 
management of patients with coronary stents and dual antiplatelet therapy represents an 
increasingly frequent issue for urologists and anesthesiologists. Most of the time, the urologist is 
the first physician to inform the patient about his future operation. However, surgeons are often 
not sufficiently aware of the high risk of withdrawing antiplatelet agents before surgery in 
patients after myocardial infarction (MI) or implantation of coronary stents 1,2. Long-term dual 
antiplatelet therapy (aspirin and clopidogrel) is particularly important in the perioperative period 
because it represents the basis of the secondary prevention after acute coronary syndrome (ACS) 
and MI and the cornerstone of the treatment following PCI with placement of bare-metal (BMS) 
or drug-eluting (DES) stents.  
In this review we assess the current scientific evidence and evaluate whether it is possible to 
propose recommendations concerning the management of urologic patients under antiplatelet 
therapy. 
 
 
ANTIPLATELET AGENTS 
 
Antiplatelet agents (AP) are classified into three categories: acetylsalicylic acid (aspirin), 
thienopyridines (clopidogrel and prasugrel) and platelet GP-IIb-IIIa inhibitors (eptifibatide, 
tirofiban, abciximab). This review deals mainly with aspirin and clopidogrel, since there is no 
perioperative experience with prasugrel, and GP-IIb-IIIa inhibitors are only used in ACS and 
immediately after PCI.  
 
Aspirin inhibits irreversibly thromboxane A2 and prostacyclin (PGI2) synthesis. It is effective in 
doses ranging between 50 and 160 mg/day. There is no evidence that doses greater than 160 
mg/day are more efficacious in reducing the cardiovascular risk, but they increase the risk of 
gastric bleeding. After cessation of aspirin, platelet aggregation returns to baseline in 5 days. The 
long-term benefit of aspirin is a relative risk reduction (RRR) of recurrent vascular events of 38% 
after MI and 25% after stroke [3]. 
 
Clopidogrel is a pro-drug oxidized by hepatic cytochromes into an active metabolite which has a 
plasma elimination half-life of 8 hours and inhibits irreversibly platelet aggregation in a dose-
dependant fashion (daily dosage: 75 mg). Seven days after cessation, 80% of platelets have 
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recovered normal aggregation. There are no major differences in terms of bleeding between 
aspirin and clopidogrel when administered alone. The benefit of dual therapy (aspirin and 
clopidogrel) over aspirin alone has been clearly demonstrated: the 1-year RRR is 31% after PCI 
and stent; beyond 1 year, the benefit of dual therapy is less pronounced (RRR 23%) [4], but keeps 
its efficiency over aspirin alone after PCI and DES: the rate of MI and death is 3.1% in patients 
still on clopidogrel at 2 years, but 7.2% when stopped at 6 months [5]. 
 
EVIDENCE ACQUISITION  
A PubMed search was conducted for articles published during the last 10 years using the 
following key words: antiplatelet agents withdrawal, perioperative antiplatelet agents and 
coronary stents, perioperative antiplatelet agents after cerebrovascular accidents, antiplatelet 
agents and management of surgical bleeding, antiplatelet agents substitution and surgery. In total, 
778 papers were produced by the search, and 167 original articles matching the focus of this 
review were selected, including controlled trials, observational series, meta-analyses and 
guidelines from major medical associations. 
 
Evidence indicates that early discontinuation of antiplatelet therapy is associated with a worsened 
outcome in patients after cardiac or cerebrovascular accidents [5,6,7,8,9]. However, most of the 
data supporting maintenance of antiplatelet therapy in the perioperative period arise from case-
series and nonrandomized retrospective or prospective studies, because of the obvious ethical 
difficulties to perform a placebo-controlled randomized trial when the tested substance is possibly 
a matter of safety. The recent recommendations formulated by panels of experts [10,11,12] are 
essentially based on precautionary principles and on an empirical balance between the risks of 
vessel thrombosis when antiplatelet agents are stopped and the risk of surgical hemorrhage when 
they are maintained. The present review aims at demonstrating whether the risk of coronary 
thrombosis outweighs the risk of surgical hemorrhage when antiplatelet agents are withdrawn 
before surgery. 
 
 
ANTIPLATELET AGENTS AND CORONARY REVASCULARISATION 
 
As long as coronary stents are not fully covered by a cellular layer, they behave like unstable 
plaques and require a dual antiplatelet therapy. The metal frame of BMS is covered by smooth 
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muscle cells within 6 weeks and by a normal endothelial layer within 3 months, but only 13% of 
DES are completely covered by endothelium at 3 months and no more than 56% at 3 years [13].  
 
Several retrospective series have disclosed very high complication rates when surgery is 
performed early after PCI: the combined rate of MI and death is 10-38% within 4 weeks after 
BMS, but decreases to 3.8% and 2.8% when surgery is performed at 2 and 3 months respectively 
[14,15,16] (Figure 1). After DES, the rate of adverse cardiac events is more continuous (5.9% up 
to 12 months) and drops to 3.3% beyond 1 year, but the mortality is high (average 35%) [17].  
 
BMS are threatened by an overgrowth of the neo-endothelium, which leads to a restenosis rate of 
12-25% at 6-12 months. To prevent this phenomenon, DES are slowly eluting anti-proliferative 
agents; their rate of restenosis is lowered to 6.5% at 4 years, but the slow re-endothelialization 
necessitates a longer duration of dual antiplatelet therapy. The recommended duration of 
clopidogrel treatment of 4-6 weeks after BMS must be extended to at least 12 months after DES 
according to recent guidelines [10,11,12] based on the rate of re-endothelialisation [13] and on 
the data of clinical trials [5,6]. This duration should be considered as a minimal safety measure. 
Although rare (0.6%/year increase compared to BMS), late DES thrombosis is a catastrophic 
event with a dramatic mortality (19% to 45%), because it corresponds to the acute interruption of 
flow in a previously normal-throughout vessel. In all studies, the major independent predictor of 
stent thrombosis is antiplatelet therapy cessation. 
 
 
ANTIPLATELET AGENTS AND CEREBROVASCULAR DISEASE  
 
The combination of aspirin and clopidogrel is no more efficacious than each medication alone to 
prevent recurrent stroke, MI or death, but increases the risk of bleeding (2.6% versus 1.3%) [18]. 
The addition of extended-release dipyridamole (400 mg) to aspirin (50-150 mg) presents a RRR 
of 20% over aspirin alone without increasing the risk of hemorrhage [19]. Whereas aggressive 
antiplatelet therapy is beneficial in coronary artery disease, where most acute events are caused 
by unstable plaque rupture, intense platelet inhibition seems not efficacious for secondary stroke 
protection, where the incidence of unstable atheromatous plaque is smaller and where the rate of 
major bleeding, particularly intracranial, is dangerously increased [18]. 
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EVIDENCE FOR THROMBOTIC RISKS AT WITHDRAWAL OF ANTIPLATELET 
AGENTS 
 
Antiplatelet drugs withdrawal outside surgery  
In a prospective study, patients who stopped aspirin within two weeks preceding an ACS have a 
doubled incidence (OR 2.05) of MI and death compared to those still on continuous aspirin [7]. In 
a meta-analysis on 50'279 patients under secondary prevention for coronary artery disease, aspirin 
cessation increased cardiac complication rate three times (OR 3.14), but in patients with coronary 
stents, the cardiac risk increased ninety times (OR 89.78) [8]. Cases of acute DES thrombosis 
with MI have been reported at aspirin withdrawal up to 4 years after stent implantation. After a 
cerebrovascular accident, discontinuing aspirin increases three times (OR 3.4) the risk of 
recurrent stroke within 20 days [9]. Therefore, aspirin is recommended as a lifelong therapy, and 
its interruption is extremely dangerous. 
 
Clopidogrel cessation is the most significant independent predictor for stent thrombosis, with an 
OR of 13.74 to 57.13 [6]. Compared to patients who have taken the drug without interruption, 
patients who stopped clopidogrel during the first month after PCI and DES are 10 times more 
likely to have a fatal outcome (7.5% versus 0.7%) during the next 11 months. The 2-year rate of 
MI and death is increased 2.3-fold in patients with DES who stopped clopidogrel at 6 months 
compared to those on clopidogrel for 2 years [5].  
 
Antiplatelet discontinuation in the surgical setting 
The situation is even more risky in the perioperative period which is characterized by increased 
platelet aggregability and a decreased fibrinolysis. The early interruption of dual antiplatelet 
therapy to allow major non cardiac surgery during the first month after PCI with BMS leads to a 
cardiac mortality up to 86%, whereas it is 5% when the treatment is maintained perioperatively 
[14]. In an observational study (192 patients), the incidence of DES thrombosis after early non 
cardiac surgery (13% urologic operations) was 31% among patients who stopped clopidogrel 
before the required delay, but 0% among those who continued dual antiplatelet therapy [20]; all 
patients with stent thrombosis died. Pooling the data of different observational studies in non 
cardiac surgery among patients with coronary stents demonstrates that mortality is directly related 
to the delay between coronary revascularisation and noncardiac surgery in patients taken off their 
antiplatelet therapy before surgery (Figure 2): the shorter the delay, the higher the mortality. 
Maintaining the antiplatelet drugs lowers dramatically the mortality: 5% instead of 85% and 0% 
instead of 31% [14,20]. 
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EVIDENCE FOR SURGICAL HAEMORRHAGE UNDER ANTIPLATELET THERAPY 
 
Hemorrhagic risks in urologic surgery 
The three best investigated interventions regarding antiplatelet therapy are transrectal biopsy of 
the prostate (P-Bx), transurethral resection of the prostate (TUR-P) and ureteroscopy (UE). A 
study following 1810 Patients after P-Bx found no statistical increase in bleeding complications 
when aspirin was maintained (3.7% vs 2.5%) [21]. Two prospective, randomized trials found no 
significant difference in the incidence of hematuria, hematospermia or rectal bleeding in patients 
maintained on aspirin during P-Bx, although the duration of bleeding was significantly prolonged 
22,23. A study including 387 patients found an increase in minor bleeding complications with a 
higher incidence and duration of hematuria and rectorrhagia, but no difference in severe bleeding 
24. 
 
Flexible UE with stone disintegration (Holmium:YAG Laser) appears to be safe under 
clopidogrel or aspirin 25. None of the procedures had to be terminated due to poor visibility 
from bleeding. There was no difference in stone-free rate, intraoperative and postoperative 
complications or hemorrhagic adverse events. Although the haemoglobin decrease was greater 
when antiplatelet agents were maintained (0.6 g/dl vs. 0.2 g/dl, p>0.0001), the difference was 
clinically not relevant.  
 
For conventional TUR-P the relationship between increased postoperative haemorrhage and use 
of aspirin was first documented in 1993 [26] and underlined by a retrospective analysis showing 
that more blood units were administered in patients taking aspirin [27]. These early studies 
therefore recommended the withdrawal of non-steroidal anti-inflammatory drugs one week before 
TUR-P. This recommendation was challenged by studies showing no significant increase in blood 
loss if patients were taking aspirin [28,29]. However, a higher incidence of late bleeding with 
tamponade of the urinary bladder requiring emptying in the operating room was found [29]. A 
randomized controlled study found that patients taking 150 mg aspirin showed no difference in 
intraoperative hemorrhage, operation time and amount of tissue resected, but an increase in 
postoperative blood loss of 51% (284 ml versus 144 ml) [30]. There was no difference in time to 
catheter removal and hospital stay. The number of patients requiring blood transfusion was higher 
in the aspirin group, although only three patients (11%) received three or more units of blood. 
The early re-initiation of aspirin if stopped 5 days prior to TUR-P was investigated in a cohort of 
120 patients [31]. Starting aspirin 24h after discontinuation of the bladder irrigation or 3 weeks 
after surgery did not influence the time to catheter removal or persistent hematuria. 
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Holmium laser enucleation and vaporization of the prostate (KTP Laser) offer new methods to 
reduce bleeding during TUR-P in patients under antiplatelet therapy [31,32]. The published 
reports show no significant increase in postoperative complications if aspirin and/or clopidogrel 
are continued throughout surgery. Furthermore, the long-term functional results are comparable. 
In summary, there are evidences that P-Bx, flexible nephroscopy and TUR-P can be performed 
under antiplatelet agents.  
 
The fact that many urologic procedures have not been investigated prevents from making 
meaningful recommendations for larger urologic surgeries including nephrectomy, cystectomy or 
prostatectomy. In radical prostatectomy, the technique of robotic assistance, combining the 
increased abdominal pressure with a more intuitive handling of surgical instruments, shows a 
trend towards lower blood loss during surgery [33]. The average blood loss in patients without 
antiplatelet therapy using robotic assistance is 100-200 ml [34] compared to 800 ml for 
conventional radical prostatectomy [35]. Whether this holds true for patients under antiplatelet 
therapy remains to be studied.  
 
When taking other noncardiac surgeries into account to try to define a strategy for urologic 
patients, we realized that large randomized trials comparing the effects of antiplatelet agents with 
placebo in surgical settings are also lacking. Most data are provided by retrospective or 
observational studies, usually of low level of evidence and underpowered to answer the question 
of the increase in operative morbidity and mortality due to aspirin or dual antiplatelet therapy. A 
meta-analysis of non-urologic surgeries including 474 studies comparing surgical bleeding of 
patients operated with or without aspirin reports an average intraoperative hemorrhagic risk 
increased 1.5-fold under aspirin, but no change in the mortality and complication rates [36]. 
Transfusion rate is increased by 20% in some orthopedic operations. Surgical data comparing 
aspirin and clopidogrel alone are lacking, but in nonsurgical trials the rate of spontaneous 
hemorrhage is similar with both drugs [4]. Dual antiplatelet therapy, however, is associated with 
an average 50% increase in surgical hemorrhage, but the clinical evidence is limited to some 
observational series in vascular [37], visceral [38] and transbronchial [39] surgery. There is an 
increase in oozing and diffuse bleeding, but no increase in major blood loss [16,20] in major non 
urologic surgeries. There is no clear increase in morbidity and mortality outside intracranial 
neurosurgery. Three studies have compared the rate of perioperative transfusion during non 
urologic surgeries for patients with and without dual antiplatelet therapy. It was not found to be 
statistically different, although there is a slight trend towards an increased rate under dual 
antiplatelet therapy: 43% versus 38% [15], 24% versus 20% [20], and 15.4% versus 15.0% [17].  
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EVIDENCE SYNTHESIS 
The available reports indicate that the increase in blood loss related to the perioperative upholding 
of aspirin and clopidogrel does not appear as a cause of potential increase in surgical 
complications or mortality, except in two conditions: 1) when bleeding occurs in a closed space 
like the skull, the spinal canal or the posterior chamber of the eye, and 2) when surgery is 
accompanied by massive hemorrhage and difficult hemostasis [40]. Many of the urologic 
operations have to be placed into the difficult hemostasis group, including partial nephrectomy, 
prostate surgery and cystectomy. From the survey of the current literature, we estimate that the 
average increase in bleeding during noncardiac surgery is about 20% with aspirin and up to 50% 
with dual antiplatelet therapy; the transfusion rate is inconsistently affected [15,17,20]. The 
global disadvantage of being transfused (short-term complications 0.4% [41], long-term survival 
reduced by 16% [42]) is far less than the 35% average mortality when the drugs are withdrawn 
before surgery. Nevertheless, blood transfusions should be avoided as far as possible by treating 
preoperative anemia and resorting to a highly trained surgical team familiar with modern blood 
sparing techniques and strategies. 
 
The risk of MI and the mortality of patients operated on adequate antiplatelet therapy should be 
the same as in stable coronary artery disease: MI rate of 2-6% and mortality 1-5% depending on 
the surgical procedure [40]. However, the risk of withdrawing antiplatelet therapy is associated 
with a MI rate of 20-40% and a mortality of 19-85%, depending on the delay between 
revascularisation and surgery. Therefore, the risk of coronary thrombosis appears higher than the 
risk of surgical hemorrhage. Pending high level of evidence data on the risk / benefit balance of 
stopping versus continuing antiplatelet therapy, preoperative cessation of aspirin and/or 
clopidogrel should be avoided as far as possible. 
 
 
CURRENT RECOMMENDATIONS AND PROPOSALS  
 
It is challenging to define clear-cut recommendations for urologic patients because this 
population hat not been sufficiently studied. However, the most recently published guidelines 
[10,11,12] have all concluded that premature discontinuation of antiplatelet therapy before 
surgery is exceedingly dangerous due to the dramatic increase in MI and death.  
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Aspirin has recently been recommended to be a lifelong therapy which should be continued 
perioperatively when prescribed in secondary prevention after ACS, MI, stroke, vascular surgery 
or PCI with any type of stent, whatever is the delay since the procedure [11,40]. In primary 
prevention, there are no studies showing that interruption of aspirin carries an increased 
perioperative risk except in diabetic patients.  
 
Dual antiplatelet therapy is recommended during 2 weeks after simple angioplasty, 4-6 weeks 
after BMS and at least 12 months after DES (Table 1) [10,40]. All elective surgical procedures 
should be postponed beyond these delays. Only vital surgery should be performed when the 
patients are still on aspirin and clopidogrel [11]. Unless the hemorrhagic risk is excessive, dual 
therapy should not be interrupted for surgery during the first 6 weeks after BMS and at least 12 
months after DES. In secondary prevention of stroke, clopidogrel or dual therapy have not been 
proven more efficacious than aspirin alone or aspirin and dipyridamole; therefore, it seems safe to 
stop clopidogrel, but not aspirin, 5 days before surgery [9,18].   
 
If clopidogrel must be interrupted 5 days preoperatively for surgical reasons in high-cardiac risk 
situations, aspirin should be continued without interruption [43]. Clopidogrel could be substituted 
with a short-acting equivalent drug. Although not proven by any controlled trial, a bridge with an 
anti-GP IIb/IIIa agent like eptifibatide or tirofiban (half-live 2 hours) has been described as a 
possible substitution for clopidogrel [44,45]. The substance is administered in continuous 
infusion for 3-5 days before the operation and stopped 6 hours preoperatively. There is no 
scientific evidence to support the use of heparin in preventing intraoperative stent thrombosis 
[10,11]. Preoperative low molecular weight heparin has been demonstrated to be without effect, 
because an antithrombin has no antiplatelet activity [7]. Although somewhat arbitrary, few 
authors have designed working algorithms based on expert opinions. The algorithm proposed 
here (Figure 3) is adapted with minor modifications from previous publications [40,46]. 
 
Since there is no antidote to antiplatelet agents, the termination of the inhibitory effect of aspirin 
and clopidogrel relies on the renewal of platelets (10%/day). It is usually estimated that the 
plasma level of a substance is negligible after 3 half-lives. Therefore, 24 hours after the last intake 
of clopidogrel (half-life of active metabolite: 8 hours) and 6 hours after the perfusion of 
eptifibatide or tirofiban (half-life: 2 hours) there is no residual antiplatelet activity in the plasma. 
During surgery, the platelets transfused after these delays will thus function normally. In this 
situation, the risk is to trigger thrombus formation inside the stents because of platelet 
overtransfusion. In order to prevent this potentially catastrophic event, it is necessary to accept 
some degree of platelet dysfunction.  
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After the operation, clopidogrel therapy needs to be restarted within the first 24 hours because of 
concerns about stent thrombosis during the postoperative phase of hypercoagulability [11]. It 
might be safer to re-initiate clopidogrel with a 300 mg loading dose which reduces the time to 
achieve maximal platelet inhibition to 4 hours and decreases the risk of hyporesponsiveness 
linked to the competition of other drugs with the hepatic cytochromes oxidizing clopidogrel into 
its active metabolite. Postoperative stent thrombosis, usually manifested as an acute MI and 
cardiogenic shock, is best treated with immediate PCI and dilatation; however, the survival rate 
with this strategy is only 65% [47]. The use of stent is questionable because the patients are at the 
peak of the acute inflammatory reaction and platelet hyperactivity.  
 
 
STRATEGIES TO PREVENT STENT THROMBOSIS 
 
In most cases, urologic surgery can be postponed by weeks or even months after the high risk 
period. This strategy alone will move most patients to the low risk group requiring a continued 
single agent antiplatelet therapy (either apirin or clopidogel). Furthermore, the operation can 
possibly be deferred by offering active surveillance strategies instead of surgery or by closely 
following small renal masses by CT instead of an acute intervention. These might be valuable 
options in patients with recent cardiovascular events. Nevertheless, many patients will still 
require continued antiplatelet therapy during their surgery. Since clear guidelines have not been 
established yet, the surgeon must base his decision on some sparse reports 2,45. 
 
A second possible strategy to prevent postoperative stent thrombosis is to avoid preoperative 
revascularisation whenever possible, because it does not benefit patients with stable [48] or even 
severe [49] coronary artery disease compared to an adequate medical therapy with tight heart rate 
control. In case of urgent or semi-urgent surgery, the risk of operating under maximal medical 
protection (-blocker, aspirin, clopidogrel, statin) is less than operating in the early phase after 
coronary revascularization.  
 
Some patients, however, may require coronary revascularisation because they suffer from an 
unstable coronary syndrome or a severe ischemia on stress testing, and present a surgical 
pathology necessitating a mandatory operation. The strategy consists of adapting the type of 
revascularization to the possible delays for noncardiac surgery (Figure 4). If the operation can be 
delayed for 6-8 weeks, the best option is a PCI with BMS or a surgical revascularization (CABG). 
If an operation is required within 2-4 weeks, the only possibility is to perform a balloon 
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angioplasty without stenting or refrain from any revascularization [11,40]. In case of emergency, 
surgery must be performed under pharmacologic cardioprotection, except in the rare cases where 
vascular surgery can be combined with simultaneous CABG. DES implantation is out of question 
because the optimal delay after DES is more than 1 year. 
 
The third strategy is to maintain dual antiplatelet therapy in the preoperative period and to resume 
the treatment as soon as possible after surgery. This applies to high cardiac risk situations (< 6 
weeks after ACS, MI, BMS or stroke, < 12 months after DES). In intermediate cardiac risk 
situations (6-24 weeks after ACS, MI or BMS, > 12 months after high-risk DES), it is advisable 
to maintain dual therapy if the risk of surgical bleeding is low, but it is possible to stop 
clopidogrel and maintain only aspirin in operations with very high hemorrhagic risk [43].  
  
 
FUTURE TRENDS 
 
Among new agents, prasugrel is a thienopyridine which acts like clopidogrel but is more potent 
and presents a much lower rate of nonresponders. It is 2-fold more efficacious than clopidogrel 
for preventing thrombosis after PCI and stenting, but it increases the non-surgical bleeding rate 
by 32% compared to clopidogrel (2.4% versus 1.8%) [50], which might raise problems in the 
surgical setting. All the data mentioned about DES concern the first-generation stents coated with 
sirolimus or paclitaxel. New devices have been introduced recently in cardiology: everolimus- or 
zotarolimus-eluting stents, and bioabsorbable stents. To date however, data on long-term outcome 
of these stents are insufficient to justify a modification of the recommendations published for 
first-generation DES. 
 
 
 
 
 
CONCLUSIONS 
 
Recent data on perioperative use of antiplatelet agents are a warning signal against their 
withdrawal before surgery when prescribed in secondary prevention after ACS, MI, coronary 
stents or stroke. In general the risk of coronary thrombosis largely outweighs the risk of surgical 
hemorrhage. However, this issue has not yet been clearly evaluated in urologic patients and in 
many instances during urologic surgery the risk of bleeding might be exceedingly dangerous. In 
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this problematic situation, a thorough dialogue between surgeon, cardiologist and anesthesiologist 
is essential to determine all risk factors and to define the best possible strategy for each individual 
patient. Although ethical difficulties prevent to perform placebo-controlled randomized trials, we 
need further prospective clinical studies to define the urologic surgeries which can safely be 
performed under continued antiplatelet therapy.  
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Table 1 
Recommendation on the duration of dual antiplatelet therapy after a coronary event 
 
 
 
Figure 1 
Incidence of major adverse cardiac events (MACE) according to the delay (months)  
between stent implantation and noncardiac surgery: MACE (major adverse cardiac event): 
myocardial infarction, in-stent thrombosis, target vessel revascularisation and death. Data from 
references 16 and 17. BMS: bare-metal stents. DES: drug-eluting stents. 
 
 
 
Figure 2 
Mortality of patients with coronary stents taken off antiplatelet drugs for noncardiac 
surgery, according to the delay since coronary revascularization: The curve is constructed 
with the pooled data from 6 observational studies (references below), and represents the 
postoperative mortality of patients taken off their antiplatelet (AP) therapy for noncardiac 
surgery, according to the delay since the coronary revascularization with bare-metal stents and/or 
drug-eluting stents. Two studies [14,20] have comparative data of mortality for patients who were 
operated without cessation of AP drugs (5% and 0%, respectively).  
References: Sharma AK, Ajani AE, Hamwi SM, Maniar P, Lakhani SV, Waksman R, Lindsay J. 
Major noncardiac surgery following coronary stenting: When is it safe to operate? Catheter 
Cardiovasc Interv 2004; 63:141-5. Schouten O, van Domburg RT, Bax JJ, de Jaegere PJ, 
Dunkelgrun M, Feringa HHH, et al. Noncardiac surgery after coronary stenting: Early surgery 
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Brotman DJ, Bakhru M, Saber W, Aneja A, Bhatt DL, Tillan-Martinez K, Jaffer AK. 
Discontinuation of antiplatelet therapy prior to low-risk noncardiac surgery in patients with drug-
eluting stents: A retrospective cohort study. J Hosp Med 2007; 2:378-84. Rhee SJ, Yun KH, Lee 
SR, Chae JK, Nam CW, Jun DH, Jeong JW. Drug-eluting stents thrombosis during perioperative 
period. Int Heart J 2008; 49:135-42. Kim HL, Park KW, Kwak JJ, Kim YS, Sir JJ, Lee SJ, et al. 
Stent-related cardiac events after noncardiac surgery: Drug-eluting stent vs bare-metal stent. Int J 
Cardiol 2008; 123:353-4 
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Figure 3 
Algorithm for the preoperative management of patients under antiplatelet therapy: (adapted 
and updated from ref 40). 1) Secondary prevention: aspirin given after a previous event 
(myocardial infarction, acute coronary syndrome, PCI & stent, CABG, PAD and stroke) or in 
documented cardiovascular disease. High-risk patients: diabetics and patients with multiple risk 
factors. 2) High-risk stents : multiple stents, long stent, proximal location (left main) and 
bifurcation lesions, patients with previous stent thrombosis. 3) Vital surgery : operations which 
are mandatory for the long-term survival of the patient. The recommended delay between drug 
interruption and surgery is 5 days for aspirin and for clopidogrel. 4) Excessive risk of bleeding: 
invasive surgery associated with severe bleeding and difficult hemostasis, including extensive 
urologic operations, or bleeding in closed spaces. In these situations, the risk/benefit ratio of 
upholding vs. withdrawing aspirin & clopidogrel must be evaluated for each case individually; in 
case of withdrawing, postoperative re-institution (with a clopidogrel loading dose of 300 mg) 
within 24 hours is important. These remarks apply also to prasugrel. 5) Substitution for 
clopidogrel (stop 5 days) is 3-5 days iv perfusion of eptifibatide or tirofiban. ACS: acute coronary 
syndrome. MI: myocardial infarction. PCI: percutaneous coronary intervention. PAD: peripheral 
arterial disease. CABG: coronary artery bypass graft surgery. 
 
 
Figure 4 
Algorithm of the strategies to decrease the risk of stent thrombosis in case of coronary 
revascularization and urgent or semi-urgent noncardiac surgery 
 
 
* Except in closed-space surgery (intracranial neurosurgery, surgery of the medullary canal, 
surgery of the posterior chamber of the eye) and invasive surgery with severe bleeding and 
difficult hemostasis. PCI: percutaneous coronary intervention. BMS : bare-metal stents. CABG : 
coronary artery bypass graft surgery. 
 
